China SXT Pharmaceuticals, Inc.
Key statistics
from XBRL data in SEC filingsAI briefing
from the latest 10-K, 10-Q and 8-K eventsChina SXT Pharmaceuticals is a British Virgin Islands holding company that sells traditional Chinese medicine products in China through a consolidated variable interest entity, with revenue declining to $1.1M in fiscal 2026.
What they do
China SXT Pharmaceuticals, Inc. is a BVI-incorporated holding company with no material operations of its own. It conducts operations in China through subsidiaries and Jiangsu Suxuantang Pharmaceutical Co., Ltd., a variable interest entity (VIE) that it consolidates under U.S. GAAP via contractual arrangements. The company is listed on the NASDAQ Capital Market under the ticker SXTC and had 958,077 Class A ordinary shares outstanding as of March 31, 2026.
Revenue drivers
- Traditional Chinese medicine products — Revenue is generated from the sale of pharmaceutical preparations through the China-based VIE, Jiangsu Suxuantang Pharmaceutical Co., Ltd. Total annual revenue declined from $2.6M in fiscal 2022 to $1.1M in fiscal 2026.
Recent performance
Fiscal 2026 revenue was $1.1M, down from $1.7M in fiscal 2025 and $2.6M in fiscal 2022. Net loss widened to $6.2M in fiscal 2026 from $3.3M in fiscal 2025. Operating cash flow was negative $4.0M in fiscal 2026, compared to negative $2.3M in fiscal 2025. Diluted EPS was negative $9.13 in fiscal 2026. As of March 31, 2026, the company reported $28.2M in cash and equivalents against $5.0M in total liabilities.
Strategy
The filing does not describe specific growth initiatives, product development plans or capital allocation priorities. The company operates through a VIE structure and acknowledges that the VIE Agreements have not been tested in a Chinese court. Its board amended the memorandum and articles of association in September 2023 to change the par value of ordinary shares from $0.08 per share to no par value. No forward-looking strategic targets are provided in the excerpts.
Risks
- VIE structure enforceability — The company relies on contractual arrangements with the VIE that have not been tested in a court of law in China, and a government finding against the structure could materially change operations.
- Declining revenue and widening losses — Revenue fell to $1.1M in fiscal 2026 from $2.6M in fiscal 2022, while net loss widened to $6.2M, increasing pressure on the business.
- Negative operating cash flow — Operating cash flow has been negative for four consecutive years, reaching negative $4.0M in fiscal 2026, which may require external funding.
- PRC regulatory risk — The company is subject to risks and uncertainties about future actions of the PRC government, including regulatory review of overseas listings through special purpose vehicles.
Outlook
The filing excerpts do not include management guidance or forward-looking statements about future revenue, profitability or cash flow. The company's financial trend shows declining revenue and widening losses through fiscal 2026.